ThermoGenesis reveals intellectual property acquisition by ImmuneCyte
By Akshay Kedari  Date: 2020-04-14

ThermoGenesis reveals intellectual property acquisition by ImmuneCyte

ThermoGenesis Holdings, Inc. has recently announced the acquisition of intellectual property by ImmuneCyte Life Sciences, its joint venture. The acquisition has been made by ThermoGenesis, a market leader and pioneer in the development & commercialization of automated cell processing technologies, to develop full human antibody therapeutics for COVID-19 disease.

The intellectual property that has been procured includes 4 monoclonal antibody drug candidates with high affinity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as tools for quantifying and screening efficacy of the neutralizing antibodies. These high-affinity antibodies have been obtained by screening the enriched libraries of B cell from people who have recovered from the COVID-19 disease recently. These technologies were developed by a team of researchers who work under East China Normal University, which is a prestigious university in China. The deal also includes an upfront cash payment for an undisclosed sum as well as low double-digit revenue sharing for the drug candidates.

The recent acquisition is another step towards the development of drug candidates or vaccine for emergency treatment of the patients infected by coronavirus. The convalescent plasma therapy has been applied for this treatment by giving current patients an infusion of plasma from individuals recovered from the disease. ThermoGenesis is developing this therapy by using its IgG/IgM Antibody Fast Detection Kit for SARS-CoV-2. Through the combination of this detection kit with the newly acquired technology by ImmuneCyte, the company will detect individuals who have acquired protective immunity against the coronavirus. Its proprietary cell processing platform will then allow the simultaneous isolation of immune cells and convalescent plasma for the effective development of potential anti-COVID-19 antibody.

The entrance of coronavirus into the cells can be blocked effectively by neutralizing antibodies, which are key effectors in the convalescent plasma, thus achieving anti-viral effects. The recent acquisition can lead to the further development of purified anti-COVID-19 monoclonal and polyclonal neutralizing antibodies as these can be more potent and safer with higher efficacy as compared to convalescent plasma.

Source credit:

https://thermogenesis.com/thermogenesis-announces-its-immunecyte-joint-venture-acquires-key-technologies-to-develop-fully-human-polyclonal-and-monoclonal-antibody-therapeutics-for-covid-19/

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Rivian secures USD 2.65 billion months before its first vehicle launch
Rivian secures USD 2.65 billion months before its first vehicle launch
By Akshay Kedari

Electric vehicle startup, Rivian, backed by Ford Motor Co. and Amazon.com Inc., has reportedly announced an investment round of USD 2.65 billion led by T. Rowe Price, months before its first vehicle launch. Sources with knowledge of the matter state...

BMW drivers can now unlock and start cars without using their iPhone
BMW drivers can now unlock and start cars without using their iPhone
By Akshay Kedari

German multinational automobile manufacturer, Bayerische Motoren Werke AG, commonly known as BMW, has reportedly unveiled an upgraded version of its mobile car key technology, called the Digital Key Plus. This product enables iPhone users to unlock t...

FMCG firms resort to marginal hike to cope with raw material inflation
FMCG firms resort to marginal hike to cope with raw material inflation
By Akshay Kedari

The recent inflation in raw materials has reportedly prompted players in the FMCG sector to take price hike measures for their products, in a bid to maintain the revenues. According to reliable sources, some FMCG companies, including Marico, have al...

boAt raises USD 100 million in funding from Warburg Pincus
boAt raises USD 100 million in funding from Warburg Pincus
By Akshay Kedari

Indian consumer electronics brand, boAt, has reportedly secured funding of USD 100 million from Warburg Pincus, a New-York-based private equity firm, at a USD 300 million valuation. The company will utilize these funds to expand its product portfoli...

Elevar Therapeutics and Inceptua partner to commercialize Apealea®
Elevar Therapeutics and Inceptua partner to commercialize Apealea®
By Akshay Kedari

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel tre...